UBS Maintains Buy on Rapport Therapeutics, Lowers Price Target to $64
Benzinga Newsdesk 22 hours ago
Analyst RatingsNewsPrice Target
UBS analyst Joon Lee maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and lowers the price target from $71 to $64.
UBS analyst Joon Lee maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and lowers the price target from $71 to $64.